Abbott Laboratories (ABT) Stock Analysis
Latest ClaritX AI analysis ·
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dysl
| Metric | Value |
|---|---|
| Price | $98.17 |
| Market cap | $169.9B |
| Sector | Healthcare |
| Industry | Medical - Devices |
| ClaritX AI score | 86/100 |
| Price/Book | 3.35 |
| Dividend yield | 2.53% |
| Beta | 0.58 |
AI verdict
Abbott Laboratories (ABT) continues to present a remarkably asymmetric investment thesis, blending the absolute safety of a deeply entrenched Dividend King with a highly attractive valuation discount. Currently trading at $98.17, the stock sits at a steep 27.35% discount from its 52-week euphoric high of $135.13. Unlike chasing over-extended, speculative momentum equities at their absolute peaks, accumulating a fundamentally flawless healthcare titan that generates $5.00 in free cash flow per share at this depressed valuation provides a massive structural margin of safety. While recent price action has pushed the RSI down to an oversold 35.39, the underlying business is thriving, recently bolstered by the FDA's approval of new capabilities for the CardioMEMS HF System. From a risk management perspective, Abbott serves as the ultimate portfolio bedrock. The equity features a highly defensive beta of 0.583, inherently insulating investor capital from broader macroeconomic volatility and cyclical market drawdowns. Its medical device and diagnostic revenue streams are entirely inelastic, ensuring reliable cash flows regardless of economic conditions. Supported by a robust Wall Street one-year average price target of $132.84 and massive historical insider accumulation exceeding 1.3 million shares earlier this year, the current technical weakness offers a highly lucrative entry point before the impending Q3 earnings catalyst. Rating 86/100
What this score has been worth
ClaritX scores ABT 86 out of 100 (snapshot 2026-10-16).
Every ClaritX analysis is scored first and judged only on what the stock did afterwards. Across the 203 analyses that scored in the 85-89 band, the average forward return was +2.0% with a 59% win rate, -1.8pp against the S&P 500. That is a measured tendency across many names, not a forecast for ABT — roughly 41% of stocks in this band still lost money.
The full band-by-band table, including the bands that lost, is on the AI Rank Report; the live strategy arms behind it are on the AI Track Record, losses published.